Arcadia Biosciences director granted 10K options

Director Gregory D. Waller received a new option grant from Arcadia Biosciences with 10,000 underlying shares and a $0.46 exercise price.

Rhea-AI Filing Summary

Arcadia Biosciences, Inc. (RKDA) reported that director Gregory D. Waller received a grant of stock options for 10,000 shares of common stock on September 10, 2026. The options have an exercise price of $0.46 per share, expire on September 10, 2036, and leave him with 23,338 options held directly after the grant. The award will become 100% vested and exercisable on the earlier of September 10, 2027 or the date of the company’s next Annual Meeting of Stockholders, subject to his continued service, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider WALLER GREGORY D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 23,338 contracts (Direct)

Footnotes (1)

1. F1. The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.

Key Figures

Options granted: 10,000 options Exercise price: $0.46 per share Options underlying shares: 10,000 shares +3 more

6 metrics

Options granted 10,000 options Stock option grant to director on September 10, 2026

Exercise price $0.46 per share Exercise price for the newly granted options

Options underlying shares 10,000 shares Common shares underlying the new stock option award

Options held after grant 23,338 options Total options held directly by Gregory D. Waller after the transaction

Option expiration date September 10, 2036 Expiration date of the newly granted options

Vesting date trigger September 10, 2027 or next Annual Meeting Earlier of these dates, subject to continued service, when options fully vest

Key Terms

Stock Option, vested and exercisable, Annual Meeting of Stockholders

3 terms

Stock Option financial

"The Option will become 100% vested and exercisable on the earlier to occur"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vested and exercisable financial

"The Option will become 100% vested and exercisable on the earlier to occur"

Annual Meeting of Stockholders regulatory

"or (ii) the date of the Issuer's next Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RKDA report for director Gregory D. Waller?

Arcadia Biosciences reported that director Gregory D. Waller received a grant of stock options for 10,000 shares of common stock on September 10, 2026, with an exercise price of $0.46 per share and expiration on September 10, 2036.

What is the exercise price of Gregory D. Waller’s new RKDA stock options?

The newly granted options to director Gregory D. Waller carry an exercise price of $0.46 per share for the underlying Arcadia Biosciences common stock, as stated in the Form 4 details.

How many Arcadia Biosciences (RKDA) options does Gregory D. Waller hold after this grant?

Following the reported grant, Gregory D. Waller holds a total of 23,338 stock options related to Arcadia Biosciences, held directly, according to the post-transaction holdings figure in the filing.

When do Gregory D. Waller’s newly granted RKDA options vest?

The options will become 100% vested and exercisable on the earlier of September 10, 2027 or the date of Arcadia Biosciences’ next Annual Meeting of Stockholders, subject to his continued service, as described in the footnote.

Do the reported RKDA insider transactions involve a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this option grant to director Gregory D. Waller.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:03 PM Accepted by SEC EDGAR 09/14/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WALLER GREGORY D

(Last) (First) (Middle)

C/O ARCADIA BIOSCIENCES, INC.

5956 SHERRY LANE, SUITE 2000

(Street)

DALLAS TEXAS 75225

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcadia Biosciences, Inc. [ RKDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.46	09/10/2026		A		10,000		(1)	09/10/2036	Common Stock	10,000	$0	23,338	D

Explanation of Responses:

1. The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.

	Gregory D. Waller, by Attorney-in-fact, Solaeta Chan	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)